115 310

Cited 0 times in

Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy

DC FieldValueLanguage
dc.contributor.author김주항-
dc.contributor.author정현철-
dc.contributor.author라선영-
dc.contributor.author홍수정-
dc.contributor.author문용화-
dc.contributor.author박병우-
dc.contributor.author박세호-
dc.contributor.author손주혁-
dc.contributor.author구자승-
dc.contributor.author이수현-
dc.contributor.author김승일-
dc.contributor.author정민규-
dc.date.accessioned2014-12-19T17:36:03Z-
dc.date.available2014-12-19T17:36:03Z-
dc.date.issued2012-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/91715-
dc.description.abstractThrough this study, we aimed to validate several biomarkers that have been known to possibly predict the outcomes of the trastuzumab and paclitaxel (TP). Human epidermal growth factor 2 (HER2) positive metastatic breast cancer (MBC) patients who had been treated with TP in single institute from 2006 to 2009 were included in this study. For procured formalin fixed paraffin embedded tumor tissues, HER2 amplification index (AI) and polymorphisms of the immunoglobulin G fragment C receptors (FCGR) were assessed as biomarkers to the trastuzumab and expression of class III beta tubulin (bTubIII) was evaluated as a predictive factor to the paclitaxel. Of 46 patients treated with TP, 27 patients could be evaluated for HER2 AI, 31 for bTubIII, and 26 for FCGR gene polymorphism. The median of the HER2 AI was 5.0 (range, 1.4-15.5) and a higher HER2 AI (≥ 5.0) was significantly correlated with better response rate (RR) (80% vs. 42%, P=0.049) and longer progression-free survival (PFS) (13.6 vs. 6.9 months, P=0.023). High bTubIII expression showed higher RRs than did low expression (81% vs. 40%, P=0.040) in addition to longer PFS (16.2 months vs. 8.8 months, P=0.04). However, polymorphisms in FCGR 2A-H131R or FCGR 3A-V158F were not predictive of RR or PFS. Our results suggest that a high HER2 AI and high bTubIII expression could be predictive of the outcomes to TP therapy but no evidence was found in terms of FCGR polymorphisms.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntibodies, Monoclonal, Humanized/adverse effects-
dc.subject.MESHAntibodies, Monoclonal, Humanized/therapeutic use*-
dc.subject.MESHBreast Neoplasms/drug therapy*-
dc.subject.MESHBreast Neoplasms/genetics*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHGene Amplification*-
dc.subject.MESHHumans-
dc.subject.MESHIn Situ Hybridization, Fluorescence-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMultivariate Analysis-
dc.subject.MESHPaclitaxel/adverse effects-
dc.subject.MESHPaclitaxel/therapeutic use*-
dc.subject.MESHPrognosis-
dc.subject.MESHReceptor, ErbB-2/genetics*-
dc.subject.MESHTrastuzumab-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHTubulin/metabolism*-
dc.titleOverexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Pathology (병리학)-
dc.contributor.googleauthorMinkyu Jung-
dc.contributor.googleauthorJa Seung Koo-
dc.contributor.googleauthorYoung Wha Moon-
dc.contributor.googleauthorByeong-Woo Park-
dc.contributor.googleauthorSeung Il Kim-
dc.contributor.googleauthorSeho Park-
dc.contributor.googleauthorSoo Hyun Lee-
dc.contributor.googleauthorSoojung Hong-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorJoohyuk Sohn-
dc.identifier.doi23028798-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00945-
dc.contributor.localIdA03773-
dc.contributor.localIdA04410-
dc.contributor.localIdA01370-
dc.contributor.localIdA01475-
dc.contributor.localIdA01524-
dc.contributor.localIdA01995-
dc.contributor.localIdA00198-
dc.contributor.localIdA00658-
dc.contributor.localIdA03606-
dc.contributor.localIdA02898-
dc.contributor.localIdA01316-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid23028798-
dc.subject.keywordAdult-
dc.subject.keywordAged-
dc.subject.keywordAntibodies, Monoclonal, Humanized/adverse effects-
dc.subject.keywordAntibodies, Monoclonal, Humanized/therapeutic use*-
dc.subject.keywordBreast Neoplasms/drug therapy*-
dc.subject.keywordBreast Neoplasms/genetics*-
dc.subject.keywordDisease-Free Survival-
dc.subject.keywordFemale-
dc.subject.keywordGene Amplification*-
dc.subject.keywordHumans-
dc.subject.keywordIn Situ Hybridization, Fluorescence-
dc.subject.keywordKaplan-Meier Estimate-
dc.subject.keywordMiddle Aged-
dc.subject.keywordMultivariate Analysis-
dc.subject.keywordPaclitaxel/adverse effects-
dc.subject.keywordPaclitaxel/therapeutic use*-
dc.subject.keywordPrognosis-
dc.subject.keywordReceptor, ErbB-2/genetics*-
dc.subject.keywordTrastuzumab-
dc.subject.keywordTreatment Outcome-
dc.subject.keywordTubulin/metabolism*-
dc.contributor.alternativeNameKim, Joo Hang-
dc.contributor.alternativeNameChung, Hyun Cheol-
dc.contributor.alternativeNameRha, Sun Young-
dc.contributor.alternativeNameHong, Soo Jung-
dc.contributor.alternativeNameMoon, Yong Wha-
dc.contributor.alternativeNamePark, Byeong Woo-
dc.contributor.alternativeNamePark, Se Ho-
dc.contributor.alternativeNameSohn, Joo Hyuk-
dc.contributor.alternativeNameKoo, Ja Seung-
dc.contributor.alternativeNameLee, Soo Hyeon-
dc.contributor.alternativeNameKim, Seung Il-
dc.contributor.alternativeNameJung, Min Kyu-
dc.contributor.affiliatedAuthorKim, Joo Hang-
dc.contributor.affiliatedAuthorChung, Hyun Cheol-
dc.contributor.affiliatedAuthorHong, Soo Jung-
dc.contributor.affiliatedAuthorMoon, Yong Wha-
dc.contributor.affiliatedAuthorPark, Byeong Woo-
dc.contributor.affiliatedAuthorPark, Se Ho-
dc.contributor.affiliatedAuthorSohn, Joo Hyuk-
dc.contributor.affiliatedAuthorKoo, Ja Seung-
dc.contributor.affiliatedAuthorKim, Seung Il-
dc.contributor.affiliatedAuthorJung, Min Kyu-
dc.contributor.affiliatedAuthorLee, Soo Hyeon-
dc.contributor.affiliatedAuthorRha, Sun Young-
dc.contributor.affiliatedAuthor구자승-
dc.citation.volume7-
dc.citation.number9-
dc.citation.startPagee45127-
dc.identifier.bibliographicCitationPLOS ONE, Vol.7(9) : e45127, 2012-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.